News and Treatment Updates
Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.
Researchers Uncover How MN1 Overexpression Causes AML
Originally Published: 05/10/2021
Article Source: External Web Content
Meningioma-1 (MN1) is a protein whose overexpression has been linked to acute myeloid leukemia (AML) and brain tumors, and 70% to 80% of AML patients with high overexpression of MN1 die within two years. Yet the mechanism by which MN1 causes these diseases has largely remained a mystery.
“Looking at the sequence, the protein has no obvious structure,” said Kathrin M. Bernt, MD, a pediatric oncologist in the Cancer Center’s Leukemia and Lymphoma Program at Children’s Hospital of Philadelphia (CHOP). “MN1 doesn’t resemble other typical oncogenes – or any other proteins – so it’s difficult to...
“If it’s the time, it’s the time”: Existential communication in naturally-occurring palliative care conversations with individuals with advanced cancer, their families, and clinicians
Originally Published: 05/10/2021
Article Source: External Web Content
Highlights
We analyzed naturally-occurring inpatient palliative care conversations.
Existential communication is pervasive and varied in palliative care conversations
Patients, families, and clinicians talk about time, the self, and connectedness.
Findings help develop a lexicon for everyday existential communication.
(Article continues at link.)
Aplastic Anemia and MDS International Foundation and NORD Launch New Natural History Study of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Originally Published: 05/06/2021
Article Source: Press Release
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia
Originally Published: 05/03/2021
Article Source: External Web Content
Key Points
Mesothelin is aberrantly expressed in over one third of childhood and young adult AML and not expressed on normal hematopoietic cells.
Mesothelin is successfully targeted in vitro and in xenograft models of MSLN+ AML with ADCs.
Abstract
In an effort to identify acute myeloid leukemia (AML)-restricted targets for therapeutic development in AML, we analyzed the transcriptomes of 2051 children and young adults with AML and compared the expression profile with normal marrow specimens. This analysis identified a large cohort of AML-restricted genes with high expression in AML, but low...
Unmet Needs of Individuals Living with Higher-Risk Myelodysplastic Syndromes: Perspectives from the Global Patient Advocacy Community
Originally Published: 05/03/2021
Article Source: External Web Content
In 2019, an in-depth Global Myelodysplastic Syndromes (MDS) Patient Advocacy Roundtable was held in Amsterdam, The Netherlands. The goal of this roundtable, which was sponsored by Takeda Oncology, was to provide patient advocates with an opportunity to share their perspectives on the challenges faced by individuals living with higher-risk MDS.
This publication shares the insights of patient advocacy community leaders regarding individuals with higher-risk MDS, including their advice for patients to support shared decision-making, patient education, and patient empowerment approaches. The...
Integration of Cellular Therapy Jumpstarts Research Efforts in Acute Leukemias
Originally Published: 04/27/2021
Article Source: External Web Content
With the goal of capitalizing on the efficacy observed with cellular therapies in acute leukemias, ongoing research efforts are underway to address unanswered questions regarding the role of transplant in conjunction with cellular therapy, optimal toxicity management, antigen escape, and methods to overcome myelosuppression and immunosuppression in these diseases, said Michael Grunwald, MD.
“Our ability to use cellular therapies to treat acute leukemias is expanding,” said Grunwald. “We have new non-transplant therapies coming along, some [of which] might be used as adjuncts to transplant...
Long‐term Results of Low‐intensity Chemotherapy with Clofarabine or Cladribine Combined with Low‐Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia
Originally Published: 04/26/2021
Article Source: External Web Content
Abstract
Background
The treatment of older patients with newly diagnosed acute myeloid leukemia (AML) using intensive chemotherapy is associated with treatment intolerance and poor survival. We evaluated two new lower‐intensity regimens with clofarabine (n=119) or cladribine (n=129) combined with low‐dose cytarabine (LDAC) alternating with decitabine.
(Article Continues at Link)
RARA Agonist Plus Azacitidine Shows Encouraging Activity in Relapsed/Refractory AML
Originally Published: 04/25/2021
Article Source: External Web Content
The novel agentSY-1425 combined with azacitidine appears to be active in retinoic acid receptor alpha (RARA) superenhancer–positive newly diagnosed and relapsed or refractory acute myeloid leukemia (AML), according to the results of a phase II trial presented at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 SY-1425 is targeted to the RARA gene, a novel target in AML.
“There are hints here that this therapy may find a place with the right patient population who has relapsed and refractory AML,” said lead author Eytan M. Stein, MD, a hematologist/oncologist...
Post-Traumatic Stress Disorder Prevalent in Patients with Acute Myeloid Leukemia
Originally Published: 04/21/2021
Article Source: External Web Content
Patients with acute myeloid leukemia can experience post-traumatic stress disorder (PTSD) one month after receiving intensive chemotherapy and may benefit from supportive approach-oriented coping interventions, according to data published in Cancer.
Previously, there have been limited data regarding PTSD symptoms among patients with acute myeloid leukemia, which is a life-threatening illness. In an interview with CURE®, Dr. Hermioni L. Amonoo, lead author on this study and staff physician in the department of psychological oncology and palliative care at the Dana-Farber Cancer Institute,...
Isoform-specific and signaling-dependent propagation of acute myeloid leukemia by Wilms tumor 1
Originally Published: 04/20/2021
Article Source: External Web Content
Highlights
WT1 is an important factor for AML maintenance in multiple subtypes
WT1 acts in an isoform- and AML-subtype-specific fashion
WT1 binding to chromatin is in balance with early growth response factors
Upregulation of expression is part of an interlinked oncogenic signaling network
Summary
Acute myeloid leukemia (AML) is caused by recurrent mutations in members of the gene regulatory and signaling machinery that control hematopoietic progenitor cell growth and differentiation. Here, we show that the transcription factor WT1 forms a major node in the rewired mutation-specific gene...